Health Care Policy Reform Agenda Puts 'Reverse Payment' Agreements Between Branded And Generic Drug Makers In The Spotlight: Proposals To Ban Payments Gaining Momentum
The Metropolitan Corporate Counsel
October 2009
The article addresses recent and upcoming developments regarding “reverse payment” pharmaceutical settlements, including an unresolved circuit split, harmonization of Department of Justice and Federal Trade Commission antitrust approaches, and a flurry of pending legislation. Proposals to ban reverse payments are gaining momentum and have significant implications for companies that develop, produce, and market branded or generic drugs, and may affect the cost and availability of drug products.

Partner Sarah Roller contributed to the article.